Virus Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Virus Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Influenza
Adventrx and TRx Pharma Announce Zanaflu Registered as the Brand Name for ANX-211 (Chitosan Gel)
April 10th, 2007
ADVENTRX Pharmaceuticals, Inc., (AMEX:ANX), a biopharmaceutical research and development company focused on commercializing proprietary product candidates for the treatment of cancer and infectious diseases, and TRx Pharma announced that Zanaflu(R) has been registered as the brand name for ANX- 211 (chitosan gel), a new product for the common cold and influenza. TRx Pharma plans to launch Zanaflu for the 2007 cold and influenza season. "Since acquiring the U.S. rights to chitosan gel from ADVENTRX in October of 2006, TRx Pharma has moved quickly to ensure an effective launch for the product this year," said Brian M. Culley, Chief Business Officer of ADVENTRX. "Drawing...
Source: Virus Weekly (2007-04-10)
|
